vs
Side-by-side financial comparison of First Foundation Inc. (FFWM) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $48.4M, roughly 1.9× First Foundation Inc.). Vericel Corp runs the higher net margin — 25.0% vs -97.9%, a 122.9% gap on every dollar of revenue. On growth, First Foundation Inc. posted the faster year-over-year revenue change (421.7% vs 23.3%). Vericel Corp produced more free cash flow last quarter ($12.8M vs $-35.2M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs -2.7%).
John B. Lacson Colleges Foundation (Bacolod), Inc. is a private maritime college in Bacolod, Negros Occidental, Philippines.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
FFWM vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $48.4M | $92.9M |
| Net Profit | $-8.0M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | -97.5% | 24.1% |
| Net Margin | -97.9% | 25.0% |
| Revenue YoY | 421.7% | 23.3% |
| Net Profit YoY | 43.0% | 17.3% |
| EPS (diluted) | $-0.09 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $48.4M | $92.9M | ||
| Q3 25 | $63.6M | $67.5M | ||
| Q2 25 | $51.4M | $63.2M | ||
| Q1 25 | $71.4M | $52.6M | ||
| Q4 24 | $9.3M | $75.4M | ||
| Q3 24 | $9.2M | $57.9M | ||
| Q2 24 | $57.5M | $52.7M | ||
| Q1 24 | $51.1M | $51.3M |
| Q4 25 | $-8.0M | $23.2M | ||
| Q3 25 | $-146.3M | $5.1M | ||
| Q2 25 | $-7.7M | $-553.0K | ||
| Q1 25 | $6.9M | $-11.2M | ||
| Q4 24 | $-14.1M | $19.8M | ||
| Q3 24 | $-82.2M | $-901.0K | ||
| Q2 24 | $3.1M | $-4.7M | ||
| Q1 24 | $793.0K | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | -97.5% | 24.1% | ||
| Q3 25 | -92.7% | 5.1% | ||
| Q2 25 | -21.1% | -3.2% | ||
| Q1 25 | 8.8% | -24.3% | ||
| Q4 24 | -247.7% | 24.5% | ||
| Q3 24 | -1276.7% | -4.3% | ||
| Q2 24 | 4.6% | -11.5% | ||
| Q1 24 | -0.2% | -10.7% |
| Q4 25 | -97.9% | 25.0% | ||
| Q3 25 | -230.1% | 7.5% | ||
| Q2 25 | -15.0% | -0.9% | ||
| Q1 25 | 9.7% | -21.4% | ||
| Q4 24 | -152.2% | 26.3% | ||
| Q3 24 | -896.9% | -1.6% | ||
| Q2 24 | 5.4% | -8.9% | ||
| Q1 24 | 1.6% | -7.5% |
| Q4 25 | $-0.09 | $0.46 | ||
| Q3 25 | $-1.78 | $0.10 | ||
| Q2 25 | $-0.09 | $-0.01 | ||
| Q1 25 | $0.08 | $-0.23 | ||
| Q4 24 | $-0.24 | $0.40 | ||
| Q3 24 | $-1.23 | $-0.02 | ||
| Q2 24 | $0.05 | $-0.10 | ||
| Q1 24 | $0.01 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.6B | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $912.6M | $354.6M |
| Total Assets | $11.9B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6B | $137.5M | ||
| Q3 25 | $1.7B | $135.4M | ||
| Q2 25 | $1.1B | $116.9M | ||
| Q1 25 | $1.0B | $112.9M | ||
| Q4 24 | $1.0B | $116.2M | ||
| Q3 24 | $1.1B | $101.7M | ||
| Q2 24 | $1.4B | $102.5M | ||
| Q1 24 | $1.6B | $110.6M |
| Q4 25 | $912.6M | $354.6M | ||
| Q3 25 | $917.9M | $321.9M | ||
| Q2 25 | $1.1B | $306.8M | ||
| Q1 25 | $1.1B | $295.5M | ||
| Q4 24 | $1.1B | $292.0M | ||
| Q3 24 | $1.1B | $257.5M | ||
| Q2 24 | $933.2M | $243.0M | ||
| Q1 24 | $928.7M | $233.9M |
| Q4 25 | $11.9B | $488.0M | ||
| Q3 25 | $11.9B | $453.3M | ||
| Q2 25 | $11.6B | $435.6M | ||
| Q1 25 | $12.6B | $424.6M | ||
| Q4 24 | $12.6B | $432.7M | ||
| Q3 24 | $13.4B | $390.4M | ||
| Q2 24 | $13.7B | $376.8M | ||
| Q1 24 | $13.6B | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-31.9M | $15.0M |
| Free Cash FlowOCF − Capex | $-35.2M | $12.8M |
| FCF MarginFCF / Revenue | -72.8% | 13.8% |
| Capex IntensityCapex / Revenue | 6.9% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $-45.9M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-31.9M | $15.0M | ||
| Q3 25 | $9.2M | $22.1M | ||
| Q2 25 | $-16.3M | $8.2M | ||
| Q1 25 | $-552.0K | $6.6M | ||
| Q4 24 | $-8.7M | $22.2M | ||
| Q3 24 | $14.2M | $10.2M | ||
| Q2 24 | $-9.1M | $18.5M | ||
| Q1 24 | $7.2M | $7.2M |
| Q4 25 | $-35.2M | $12.8M | ||
| Q3 25 | $8.6M | $19.5M | ||
| Q2 25 | $-16.7M | $81.0K | ||
| Q1 25 | $-2.5M | $-7.6M | ||
| Q4 24 | $-11.4M | $8.5M | ||
| Q3 24 | $13.4M | $-9.2M | ||
| Q2 24 | $-9.4M | $1.8M | ||
| Q1 24 | $5.9M | $-6.8M |
| Q4 25 | -72.8% | 13.8% | ||
| Q3 25 | 13.5% | 28.8% | ||
| Q2 25 | -32.4% | 0.1% | ||
| Q1 25 | -3.5% | -14.5% | ||
| Q4 24 | -123.5% | 11.2% | ||
| Q3 24 | 146.2% | -15.9% | ||
| Q2 24 | -16.3% | 3.4% | ||
| Q1 24 | 11.6% | -13.3% |
| Q4 25 | 6.9% | 2.4% | ||
| Q3 25 | 1.0% | 3.9% | ||
| Q2 25 | 0.8% | 12.9% | ||
| Q1 25 | 2.8% | 27.0% | ||
| Q4 24 | 29.4% | 18.3% | ||
| Q3 24 | 9.0% | 33.5% | ||
| Q2 24 | 0.4% | 31.8% | ||
| Q1 24 | 2.5% | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.08× | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.96× | — | ||
| Q1 24 | 9.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FFWM
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
